	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	1,160	1,327	1,778	1,905	2,056	2,292	2,832	4,814	4,936	6,041	5,041	5,554	6,813
Cost of Operating Revenue	836	1,013	1,171	1,143	1,307	1,400	1,768	2,560	2,704	3,489	3,222	3,293	3,615
Gross Profit	323	313	606	761	749	892	1,064	2,253	2,231	2,552	1,819	2,261	3,198
Gross Margin	27.9	23.6	34.1	40.0	36.4	38.9	37.6	46.8	45.2	42.2	36.1	40.7	46.9
Total Operating Expenses	983	1,188	1,500	1,602	1,767	2,100	2,453	3,467	3,762	4,747	4,646	4,929	5,508
Operating Profit	176	139	277	303	289	192	379	1,346	1,174	1,294	395	625	1,305
Operating Margin	15.2	10.5	15.6	15.9	14.1	8.4	13.4	28.0	23.8	21.4	7.8	11.3	19.2
Financing Income/(Expense) - Net	-56	-86	-110	-75	-59	-88	-90	-49	-90	-186	-174	-198	-133
Profit before Taxes	121	67	169	235	237	120	294	1,301	1,084	1,109	236	484	1,182
Income Taxes	24	-2	35	44	70	26	38	317	251	312	68	130	292
Profit after Tax	97	68	134	190	168	94	255	984	828	790	161	358	889
PAT Margin	8.4	5.2	7.5	10.0	8.2	4.1	9.0	20.4	16.8	13.1	3.2	6.5	13.0
EPS - Basic - ex Extraordinary Items	1.84	1.29	2.53	4.20	3.17	1.77	4.79	18.36	15.42	14.69	2.98	6.65	16.47
EPS - Diluted - ex Extraordinary Items	1.84	1.29	2.53	4.18	3.15	1.76	4.79	18.28	15.35	14.64	2.98	6.64	16.45
EBIT	176	139	277	303	289	192	379	1,346	1,174	1,294	395	625	1,305
EBITDA	209	201	364	409	415	356	566	1,552	1,425	1,618	779	1,055	1,785
EBITDA Margin	18.0	15.1	20.5	21.5	20.2	15.5	20.0	32.2	28.9	26.8	15.5	19.0	26.2

Balance Sheet

Abridged

Understanding Balance Sheet

Laurus Labs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	575	860	1,003	1,140	1,248	1,463	1,812	3,075	3,345	3,462	3,835	4,332	4,829
Long-Term Investments	-	8	1	24	27	33	37	46	91	50	113	116	134
Property Plant & Equipment - Net	610	844	1,084	1,356	1,627	1,717	1,774	2,277	3,209	3,700	4,048	4,316	4,879
Total Non-Current Assets	698	976	1,221	1,514	1,769	1,868	1,938	2,676	3,623	4,199	4,552	5,003	5,682
Total Assets	1,273	1,843	2,224	2,653	3,017	3,331	3,750	5,751	6,968	7,660	8,387	9,336	10,511
Total Current Liabilities	711	799	884	1,121	1,307	1,424	1,692	2,457	2,681	2,432	3,112	3,540	3,635
Long Term Debt	188	302	460	125	142	259	186	455	636	799	860	708	723
Total Non-Current Liabilities	204	323	483	202	227	349	288	693	928	1,179	1,159	1,193	1,444
Total Liabilities	915	1,122	1,367	1,323	1,534	1,773	1,981	3,150	3,609	3,612	4,271	4,733	5,080
Total Shareholders' Equity	358	721	857	1,330	1,483	1,558	1,770	2,598	3,351	4,038	4,111	4,473	5,300
Minority Interest	-	-	-	-	-	-	-	3	8	11	5	130	131
Total Equity	358	721	857	1,330	1,483	1,558	1,770	2,601	3,359	4,049	4,116	4,603	5,431
Total Liabilities & Equity	1,273	1,843	2,224	2,653	3,017	3,331	3,750	5,751	6,968	7,660	8,387	9,336	10,511

Cash Flow

Abridged

Understanding Cash Flow Statement

Laurus Labs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	133	103	236	291	324	266	462	1,270	1,169	1,173	526	773	1,434
Working Capital - Increase/(Decrease)	-59	-251	-154	-52	-57	-52	-200	-594	-342	-315	-29	-375	25
Net CF from Operating Activities	74	-148	81	238	267	214	263	676	828	858	497	399	1,459
Capital Expenditures - Net	306	382	326	277	391	254	222	684	877	987	676	541	1,063
Net CF from Investing Activities	-312	-397	-315	-290	-385	-254	-222	-942	-916	-1,001	-828	-688	-1,095
Dividends Paid - Cash - Total	-	-	-	5	16	16	32	75	86	107	86	43	86
Stock - Issuance/(Retirement) - Net	0	294	0	286	0	2	3	7	4	7	3	10	20
Debt - LT & ST - Issuance/(Retirement) - Total	250	274	206	-239	137	56	-6	380	197	214	508	156	-330
Net Cash Flow from Financing Activities	250	569	207	41	118	40	-42	313	115	114	424	249	-354
Free Cash Flow to Equity	18	-255	-39	-278	13	17	35	373	148	84	329	14	66
Free Operating CF net dividend	-235	-531	-246	-44	-140	-56	8	-88	-135	-240	-268	-286	303
Free Operating CF	-235	-531	-246	-39	-124	-40	40	-12	-49	-132	-181	-242	389

Business Segment Analysis

FY End:

Mar 26

Laurus Labs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical Ingredients and intermediates (100.0%)₹ 1,069.95 Cr

Revenue / Sales

Pharmaceutical Ingredients and intermediates (100.0%)₹ 6,812.90 Cr

Assets

Pharmaceutical Ingredients and intermediates (100.0%)₹ 10,511.19 Cr

Operating Income

Pharmaceutical Ingredients and intermediates (100.0%)₹ 1,305.14 Cr

Regional Segment Analysis

FY End:

Mar 26

Laurus Labs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India (67.1%)₹ 4,569.13 CrWithin India (32.9%)₹ 2,243.77 Cr

Historical Segment Analysis

Track how Laurus Labs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2014 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceutical Ingredients and intermediates	308	689	877	990	678	641	1,070
Eliminations	0	-	-	-	-	-	-
Infosystems	2	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Laurus Labs Ltd.?

The latest trailing twelve month revenue of Laurus Labs Ltd. is ₹ 6,812.90 Cr, reflecting a 1-year growth of 22.67% and a 3-year CAGR of 4.09%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Laurus Labs Ltd.?

The latest trailing twelve month net profit (PAT) of Laurus Labs Ltd. is ₹ 888.79 Cr, with a 3-year earnings CAGR of 3.91%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Laurus Labs Ltd.?

The trailing twelve month EBITDA of Laurus Labs Ltd. is approximately ₹ 1,297.66 Cr (based on an operating margin of 19.05%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Laurus Labs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Laurus Labs Ltd. is 16.43. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Laurus Labs Ltd.?

The debt-to-equity ratio of Laurus Labs Ltd. stands at 0.48. The interest coverage ratio is 7.60x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Laurus Labs Ltd.?

The estimated book value per share of Laurus Labs Ltd. is 99.62 (derived from a P/B ratio of 15.58 and market price of ₹ 1,551.60), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Laurus Labs Ltd.?

The trailing twelve month operating cash flow of Laurus Labs Ltd. is ₹ 1,459.38 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Laurus Labs Ltd. report consolidated or standalone financials?

Laurus Labs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.